"RVX has multiple MOA's and Amarin maybe none."
There is abundant research on the various and potential cardioprotective properties of omega-3 fatty acids. Many well documented MOAs for omega-3s like Vascepa. Lots of potential pathways modulated by apabetalone and Vascepa, but uncertain which one(s) are responsible for any MACE reduction.